A new international study introduces a precision medicine framework for Chronic Myelomonocytic Leukemia (CMML), a rare blood cancer that has lacked personalized treatment strategies. By combining genomic data with clinical information, the model improves diagnosis, survival prediction, and decisions about when to perform bone marrow transplants.
Researchers identified nine genomic subtypes covering about 69% of patients. Some groups with specific mutations have better outcomes and longer survival, while others with high-risk mutations experience more aggressive disease and shorter survival. This approach moves beyond the traditional “one-size-fits-all” method of classification.
At the center of the framework is the iCPSS (Individualized Prognostic Scoring System), which more accurately predicts survival and relapse risk than older models. It also helps doctors determine the best timing for stem cell transplants, especially important since most CMML patients are older and face higher treatment risks.